Page last updated: 2024-08-18

pyrroles and Stroke

pyrroles has been researched along with Stroke in 182 studies

Research

Studies (182)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's108 (59.34)29.6817
2010's72 (39.56)24.3611
2020's2 (1.10)2.80

Authors

AuthorsStudies
Chen, J; Lan, X; Liu, X; Song, D; Xue, J; Zhang, L; Zhang, X1
Feng, W; Islam, SMT; Khan, M; Kumar, P; Qiao, F; Singh, AK; Singh, I; Won, JS1
Chen, Q; Guan, F; Li, M; Wang, J; Wang, W; Wang, Y; Wang, Z; Zhang, W1
Bliss, TM; George, PM; Hua, T; Lee, A; Levinson, A; Mehta, S; Oh, B; Steinberg, GK; Sun, G1
Cho, S; Kim, E; Park, KW; Yang, J1
George, P; Oh, B1
Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H1
Delgado, G; Naves, M1
Balu, S; Montouchet, C; Ruff, L1
Bordet, R; Darteil, R; Duriez, P; Gautier, S; Hanf, R; Laprais, M; Ouk, T; Potey, C; Staels, B1
Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K1
Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH1
Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS1
Albers, GW; Tai, WA1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J1
Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P1
Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T1
Amarenco, P; Callahan, A; Campese, VM; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Wilson, DJ; Zivin, JA1
Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C1
Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A1
Abdel-Rahman, I; Murphy, C1
Brown, CE; Gerrow, K; Holmes, A; Lockhart, KL; Nahirney, PC; Reeson, P; Tennant, KA; Thompson, K; Wang, J; Weiser Novak, S1
Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC1
Fabiny, A1
Ago, T; Arimura, K; Kamouchi, M; Kitazono, T; Kuroda, J; Makihara, N; Nakamura, K; Nishimura, A; Ooboshi, H; Tachibana, M; Wakisaka, Y; Yoshikawa, Y1
Chen, Q; Deng, G; Li, M; Li, Q; Wan, J; Wang, J; Wang, W; Wang, Y; Yang, Q1
Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P1
Keppel Hesselink, JM1
Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K1
Deedwania, P; Singh, V1
Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM1
Császár, A1
Kim, YH; Kim, YJ; Lee, SH; Yoon, BW1
Amarenco, P; Breazna, A; Callahan, A; Chaturvedi, S; Goldstein, LB; Hennerici, M; Rudolph, A; Sillesen, H; Welch, MA; Zivin, J1
Fitchett, DH; Goodman, SG; Langer, A1
Goldstein, MR; Mascitelli, L; Pezzetta, F1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA1
Martinez, DG1
Caínzos Romero, T; Fernández Fernández, FJ; Pía Iglesias, G; Sesma, P1
Hopkins, LN; Levy, EI; Samuelson, RM; Siddiqui, AH1
Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA1
Hart, RG1
Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA1
Coull, BM; Johnston, SC1
Chen, TY; Kuo, YL; Lin, WC; Tan, TY1
Amarenco, P; Brenner, D; Gongora-Rivera, F; Jaramillo, A; Klein, IF; Labreuche, J; Lavallée, PC; Touboul, PJ; Vicaut, E1
Dahlof, B; Poulter, NR; Sever, PS; Wedel, H2
Karadağ, B; Ongen, Z; Yilmaz, Y1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA1
Caro, JJ; Kongnakorn, T; O'Brien, JA; Proskorovsky, I; Roberts, CS; Ward, A1
Welch, KM1
Tsuda, K1
Myint, PK; Niruban, A; Potter, JF1
Castilla-Guerra, L; Chaturvedi, S; Fernandez-Moreno, Mdel C; Jimenez-Hernandez, MD1
Chaturvedi, S; Goldstein, MR; Mascitelli, L; Pezzetta, F1
Chopp, M; Cui, Y; Jia, L; Lu, M; Zhang, L; Zhang, ZG1
Landau, W1
Strupp, M1
Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K1
Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD1
Nissen, SE1
Derugin, N; Ferriero, DM; Shimotake, J; Vexler, ZS; Wendland, M1
Amarenco, P; Benavente, O; Callahan, A; Goldstein, LB; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, JA; Zweifler, RM1
Cui, L; Du, W; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X1
Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J1
Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K1
Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R1
Tuttle, KR1
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS1
Huisa, BN; Stemer, AB; Zivin, JA1
Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I1
Kamran, KA; Khan, M1
Arrospide, A; Caro, J; Mar, J; Rejas-Gutiérrez, J; Vivancos-Mora, J1
Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL1
Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X1
Gaur, V; Kumar, A1
Frey, P; Waters, DD1
Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M1
Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK1
Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T1
Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C1
Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD1
Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA1
Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG1
Kasner, SE; Taylor, RA; Weigele, JB1
Sillence, D; Tchan, M1
Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA1
Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P1
Fagan, SC; Guan, W; Kozak, A1
Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P1
Ageno, W; Dentali, F; Romualdi, E; Squizzato, A1
Braunwald, E1
Shinohara, Y1
Binning, MJ; Darkhabani, Z; Levy, EI; Mokin, M; Siddiqui, AH1
Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB1
Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES1
Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK1
Blanco, M; Castillo, J; Pérez-Mato, M; Rodríguez-Yáñez, M; Sobrino, T1
Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A1
Munshi, A1
Waeber, C; Wang, QM; Wei, Y; Zheng, Y1
Degnan, AJ; Gillard, JH; Howarth, SP; Patterson, AJ; Tang, TY1
Ali, S; Iyer, RS; Krishnan, M; Kumar, S1
Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD1
Spence, JD1
Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A1
Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN1
Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A1
Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G1
Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M1
Baumgartner, RW; Georgiadis, D1
Clark, LT1
Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H3
SoRelle, R1
Chen, J; Chopp, M; Feldkamp, CS; Jiang, H; Katakowski, M; Li, Y; Lu, M; Wang, L; Wang, Y; Zhang, C; Zhang, ZG1
Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H1
Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ1
Amarenco, P; Bogousslavsky, J; Callahan, AS; Goldstein, L; Hennerici, M; Sillsen, H; Welch, MA; Zivin, J1
Brown, WV; Moussa, M1
Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK1
Gathof, BS; Gresser, U1
Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R1
Hayashi, A; Ogawa, Y; Sasamata, M; Sonoda, R; Suzuki, M1
Madsen, S1
McGowan, MP1
Chen, J; Chopp, M; Jiang, H; Katakowski, M; Li, Y; Lu, M; Robin, A; Zhang, C; Zhang, L1
Griebenow, R1
Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H1
Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S1
Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C1
Jaber, BL; Madias, NE1
Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ1
Clearfield, M1
Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD1
Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM1
Lesaffre, E; Rizopoulos, D; Tsonaka, R1
Chopp, M; Ding, G; Ewing, JR; Jiang, Q; Li, L; Panda, S; Zhang, L; Zhang, ZG1
Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM1
Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA1
Kent, DM1
Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A1
Carod-Artal, FJ1
Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA1
Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA1
Cohen, JS1
Khan, NA1
Mascitelli, L; Pezzetta, F1
Elkind, MS1
East, JE1
Heering, NJ1
Kulbertus, H1
Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N1
Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC1
Blanco, M; Castellanos, M; Castillo, J; Dávalos, A; García-Gil, M; Leira, R; Lizasoain, I; Moro, MA; Nombela, F; Rodriguez-Yáñez, M; Serena, J; Vivancos, J1
Bassi, A; Caltagirone, C; Colivicchi, F; Santini, M1
Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M1
Arca, M1
Arca, M; Gaspardone, A1
Amarenco, P1
Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD1
Armani, A; Toth, PP1
Chen, J; Chopp, M; Cui, X; Li, A; Lu, M; Roberts, C; Zacharek, A1
Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H1
Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K1
Karam, JG; Loney-Hutchinson, L; McFarlane, SI1
Bybee, KA; Lee, JH; O'Keefe, JH1
Bonnaire, B; Bugnicourt, JM; Garcia, PY; Godefroy, O; Lefranc, M; Lepage, L1
Crook, MA; Mikhailidis, DP; Wierzbicki, AS; Winder, AF1
Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC1
Basson, CT; Delanty, N; Vaughan, CJ1

Reviews

24 review(s) available for pyrroles and Stroke

ArticleYear
Conductive polymers to modulate the post-stroke neural environment.
    Brain research bulletin, 2019, Volume: 148

    Topics: Animals; Cell Differentiation; Electric Conductivity; Humans; Polymers; Pyrroles; Recovery of Function; Stroke; Stroke Rehabilitation

2019
    Hand therapy, 2016, Volume: 21, Issue:1

    Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult

2016
Expanding roles for atorvastatin.
    Drugs of today (Barcelona, Spain : 1998), 2008, Volume: 44, Issue:6

    Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke

2008
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
    Ideggyogyaszati szemle, 2008, Jul-30, Volume: 61, Issue:7-8

    Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke

2008
What's new in stroke? The top 10 studies of 2006-2008. Part II.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:12

    Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke

2008
[Atorvastatin in secondary prevention].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 2

    Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke

2009
Review of the SPARCL trial and its subanalyses.
    Current atherosclerosis reports, 2009, Volume: 11, Issue:4

    Topics: Age Factors; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrroles; Risk Factors; Sex Factors; Stroke

2009
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
    Current opinion in cardiology, 2010, Volume: 25, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke

2010
Current management of symptomatic intracranial stenosis.
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Pathologic; Endovascular Procedures; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Stents; Stroke; Tetrazoles

2011
Statins for acute ischemic stroke.
    The Cochrane database of systematic reviews, 2011, Aug-10, Issue:8

    Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Neuroprotective Agents; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Ticlopidine

2011
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator

2010
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
    Archives of internal medicine, 2003, Mar-24, Volume: 163, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome

2003
[Secondary prevention after ischemic stroke].
    Praxis, 2003, Jan-29, Volume: 92, Issue:5

    Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Smoking Prevention; Stents; Stroke; Vertebral Artery Dissection

2003
Treating dyslipidemia with statins: the risk-benefit profile.
    American heart journal, 2003, Volume: 145, Issue:3

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States

2003
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
    Current opinion in lipidology, 2003, Volume: 14, Issue:6

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome

2003
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    European journal of medical research, 2004, Jan-26, Volume: 9, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Stroke

2004
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
    The American journal of cardiology, 2005, Sep-05, Volume: 96, Issue:5A

    Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome

2005
Stroke prevention, blood cholesterol and statins.
    Acta neurologica Taiwanica, 2005, Volume: 14, Issue:3

    Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke

2005
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
    The Canadian journal of cardiology, 2006, Volume: 22, Issue:10

    Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke

2006
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Drugs, 2007, Volume: 67 Suppl 1

    Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke

2007
Atorvastatin: its clinical role in cerebrovascular prevention.
    Drugs, 2007, Volume: 67 Suppl 1

    Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke

2007
Atorvastatin in prevention of stroke and transient ischaemic attack.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:16

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Stroke

2007
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
    Current medical research and opinion, 2008, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke

2008
Statin therapy and stroke prevention.
    Current opinion in cardiology, 2001, Volume: 16, Issue:4

    Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Encephalitis; Endothelium, Vascular; Fibrinolytic Agents; Heptanoic Acids; Humans; Lovastatin; Nitric Oxide Synthase; Pyrroles; Stroke

2001

Trials

54 trial(s) available for pyrroles and Stroke

ArticleYear
Literature Commentary.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2021, 12-01, Volume: 41, Issue:4

    Topics: Aged; Aspirin; Humans; Ophthalmology; Piperidines; Pyridines; Pyrroles; Retrospective Studies; Spiro Compounds; Stroke

2021
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    European heart journal, 2013, Volume: 34, Issue:41

    Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional

2013
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
    European heart journal, 2014, Jul-14, Volume: 35, Issue:27

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2014
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    JAMA, 2014, Jan-15, Volume: 311, Issue:3

    Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome

2014
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases

2014
Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.
    Clinical neurology and neurosurgery, 2014, Volume: 120

    Topics: Aged; Atorvastatin; China; Clinical Protocols; Constriction, Pathologic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pyrroles; Single-Blind Method; Stroke; Vertebrobasilar Insufficiency

2014
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
    Atherosclerosis, 2014, Volume: 236, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult

2014
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Stroke, 2014, Volume: 45, Issue:10

    Topics: Aged; Atorvastatin; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kidney; Male; Middle Aged; Pyrroles; Stroke

2014
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:1

    Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography

2015
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome

2014
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Journal of the American College of Cardiology, 2015, Apr-21, Volume: 65, Issue:15

    Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke

2015
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Stroke, 2008, Volume: 39, Issue:9

    Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides

2008
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Atherosclerosis, 2009, Volume: 204, Issue:2

    Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides

2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Stroke, 2009, Volume: 40, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2009
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation

2009
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Stroke, 2009, Volume: 40, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult

2009
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke

2009
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Stroke, 2010, Volume: 41, Issue:3

    Topics: Atorvastatin; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Stroke

2010
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
    The American journal of cardiology, 2010, Mar-01, Volume: 105, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2010
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5

    Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome

2010
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
    European heart journal, 2010, Volume: 31, Issue:23

    Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2010
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke

2011
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Journal of the American College of Cardiology, 2011, Jan-04, Volume: 57, Issue:1

    Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors

2011
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
    Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:4

    Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome

2011
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
    Circulation. Cardiovascular quality and outcomes, 2011, Volume: 4, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome

2011
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    American heart journal, 2011, Volume: 161, Issue:5

    Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome

2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Archives of neurology, 2011, Volume: 68, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult

2011
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
    European heart journal, 2012, Volume: 33, Issue:4

    Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome

2012
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    International journal of stroke : official journal of the International Stroke Society, 2012, Volume: 7, Issue:2

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome

2012
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
    JACC. Cardiovascular imaging, 2012, Volume: 5, Issue:3

    Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification

2012
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
    Circulation, 2012, Apr-24, Volume: 125, Issue:16

    Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke

2012
Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase.
    European journal of neurology, 2012, Volume: 19, Issue:12

    Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Nitric Oxide; Pyrroles; Stem Cells; Stroke; Vascular Endothelial Growth Factor A

2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Journal of the American College of Cardiology, 2013, Jan-15, Volume: 61, Issue:2

    Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke

2013
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Circulation, 2002, Sep-24, Volume: 106, Issue:13

    Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome

2002
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Lancet (London, England), 2003, Apr-05, Volume: 361, Issue:9364

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke

2003
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Circulation, 2003, Aug-26, Volume: 108, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome

2003
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Stroke

2003
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
    The American journal of cardiology, 2004, Jan-15, Volume: 93, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors

2004
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment

2004
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2005, Volume: 12, Issue:1

    Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome

2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Drugs, 2004, Volume: 64 Suppl 2

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom

2004
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Diabetes care, 2005, Volume: 28, Issue:5

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke

2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    The New England journal of medicine, 2005, Jul-21, Volume: 353, Issue:3

    Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke

2005
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
    Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:1

    Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke

2006
High-dose atorvastatin after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, 08-10, Volume: 355, Issue:6

    Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke

2006
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:11

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors

2006
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Diabetes care, 2006, Volume: 29, Issue:11

    Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke

2006
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    The American journal of cardiology, 2007, Sep-01, Volume: 100, Issue:5

    Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome

2007
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
    Neurology, 2007, Aug-28, Volume: 69, Issue:9

    Topics: Acute Disease; Aged; Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Odds Ratio; Pyrroles; Risk Factors; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Withholding Treatment

2007
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:12

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke

2007
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke

2008
SPARCL: the glimmer of statins for stroke risk reduction.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:5

    Topics: Atorvastatin; Coronary Disease; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Stroke

2007
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    European heart journal, 2008, Volume: 29, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke

2008
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
    The American journal of cardiology, 2008, Feb-15, Volume: 101, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke

2008

Other Studies

104 other study(ies) available for pyrroles and Stroke

ArticleYear
Wnt canonical pathway activator TWS119 drives microglial anti-inflammatory activation and facilitates neurological recovery following experimental stroke.
    Journal of neuroinflammation, 2019, Dec-06, Volume: 16, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Microglia; Pyrimidines; Pyrroles; Recovery of Function; Stroke; Wnt Signaling Pathway

2019
Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke.
    Brain research, 2020, 08-15, Volume: 1741

    Topics: Aging; Alcohol Dehydrogenase; Animals; Benzamides; Disease Models, Animal; Drug Delivery Systems; Male; Mice; Mice, Inbred C57BL; Pyrroles; Recovery of Function; Stroke

2020
GSK-3β as a target for protection against transient cerebral ischemia.
    International journal of medical sciences, 2017, Volume: 14, Issue:4

    Topics: Animals; beta Catenin; Blood-Brain Barrier; Brain; Disease Models, Animal; Gene Expression Regulation; Glycogen Synthase Kinase 3 beta; Humans; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Pyrimidines; Pyrroles; Rats; Stroke; Wnt Signaling Pathway; Zonula Occludens-1 Protein

2017
Electrical preconditioning of stem cells with a conductive polymer scaffold enhances stroke recovery.
    Biomaterials, 2017, Volume: 142

    Topics: Animals; Brain Infarction; Electric Conductivity; Electric Stimulation; Gene Expression Regulation; Humans; Male; Neural Stem Cells; Polymers; Pyrroles; Rats, Nude; Recovery of Function; RNA, Messenger; Stroke; Tissue Scaffolds; Vascular Endothelial Growth Factor A

2017
Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice.
    Translational stroke research, 2018, Volume: 9, Issue:5

    Topics: Animals; Blood Glucose; Brain Edema; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose Tolerance Test; Indoles; Insulin; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Proteoglycans; Pyrroles; RNA, Messenger; Signal Transduction; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2018
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:9

    Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2019
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
    Vascular, 2014, Volume: 22, Issue:3

    Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography

2014
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States

2013
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
    Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:3

    Topics: Animals; Atorvastatin; Cerebral Cortex; Disease Models, Animal; Gene Expression; Heptanoic Acids; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase Type II; PPAR alpha; Pyrroles; Stroke; Vascular Cell Adhesion Molecule-1

2014
Secondary prevention of atherothrombotic or cryptogenic stroke.
    Circulation, 2014, Jan-28, Volume: 129, Issue:4

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Life Style; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine

2014
Recurrent ischaemic stroke unveils polycythaemia vera.
    BMJ case reports, 2015, Mar-09, Volume: 2015

    Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome

2015
Delayed inhibition of VEGF signaling after stroke attenuates blood-brain barrier breakdown and improves functional recovery in a comorbidity-dependent manner.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Apr-01, Volume: 35, Issue:13

    Topics: Animals; Blood-Brain Barrier; Brain; Capillaries; Dendritic Spines; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelial Cells; Gene Expression; Indoles; Infarction; Insulin; Mice; Permeability; Pyrroles; Recovery of Function; Signal Transduction; Stroke; Synapses; Transcytosis; Vascular Endothelial Growth Factor Receptor-2

2015
Ask the doctor. I am 61 and had been on atorvastatin for 10 years with no problems. Recently, I've had disabling muscle pain with both the generic atorvastatin and the brand-name version, Lipitor. My doctor says that I can no longer take statin drugs.
    Harvard women's health watch, 2014, Volume: 22, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Female; Health Behavior; Heptanoic Acids; Humans; Middle Aged; Muscle, Skeletal; Pyrroles; Rhabdomyolysis; Stroke

2014
Possible involvement of basic FGF in the upregulation of PDGFRβ in pericytes after ischemic stroke.
    Brain research, 2016, Jan-01, Volume: 1630

    Topics: Animals; Brain; Brain Ischemia; Cell Hypoxia; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Hydrogen-Ion Concentration; Infarction, Middle Cerebral Artery; Male; Mice, 129 Strain; Mice, Inbred C57BL; Pericytes; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Stroke; Up-Regulation

2016
GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.
    Molecular neurobiology, 2016, Volume: 53, Issue:10

    Topics: Animals; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Cerebral Hemorrhage; Claudin-3; Glycogen Synthase Kinase 3 beta; Infarction, Middle Cerebral Artery; Male; Permeability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Stroke; Tissue Plasminogen Activator; Wnt Signaling Pathway; Zonula Occludens-1 Protein

2016
NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
    Drug development research, 2017, Volume: 78, Issue:2

    Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Epilepsy; Humans; Neuralgia; Pyrroles; Receptors, AMPA; Stroke; Tetrahydroisoquinolines; Treatment Outcome

2017
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Orvosi hetilap, 2008, Jun-15, Volume: 149, Issue:24

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor

2008
Atorvastatin enhances hypothermia-induced neuroprotection after stroke.
    Journal of the neurological sciences, 2008, Dec-15, Volume: 275, Issue:1-2

    Topics: Animals; Atorvastatin; Brain Infarction; CD11b Antigen; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnetic Resonance Imaging; Male; Neurologic Examination; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stroke

2008
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Neurology, 2009, Feb-24, Volume: 72, Issue:8

    Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Risk Assessment; Stroke

2009
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:9

    Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke

2008
Hemorrhagic stroke in the SPARCL study.
    Stroke, 2008, Volume: 39, Issue:11

    Topics: Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intracranial Hemorrhages; Lipoproteins, LDL; Male; Pyrroles; Risk Factors; Stroke

2008
Binder wars.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke

2008
[Statins and stroke].
    Medicina clinica, 2008, Oct-25, Volume: 131, Issue:14

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Neovascularization, Physiologic; Pyrroles; Stroke

2008
The cost of stroke prevention.
    Stroke, 2009, Volume: 40, Issue:2

    Topics: Atorvastatin; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke

2009
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
    Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:8

    Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography

2008
Statins: not just for the young or the faint of heart.
    Neurology, 2009, Feb-24, Volume: 72, Issue:8

    Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke

2009
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
    Journal of neurology, 2009, Volume: 256, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency

2009
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Journal of hypertension, 2009, Volume: 27, Issue:5

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome

2009
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2009, Volume: 12, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Computer Simulation; Cost-Benefit Analysis; Databases, Factual; Female; Health Services; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Saskatchewan; Secondary Prevention; Stroke; Survival Analysis; United States; Young Adult

2009
Statins and gender-related difference in endothelial function in cerebral small vessel disease.
    Stroke, 2009, Volume: 40, Issue:9

    Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation

2009
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
    Stroke, 2009, Volume: 40, Issue:9

    Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Vasodilation

2009
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Neurology, 2009, Jul-21, Volume: 73, Issue:3

    Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Heptanoic Acids; Humans; Ischemic Attack, Transient; Outcome Assessment, Health Care; Pyrroles; Stroke; Treatment Outcome

2009
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Neurology, 2009, Jul-21, Volume: 73, Issue:3

    Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Hemorrhage; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Iatrogenic Disease; Ischemic Attack, Transient; Pyrroles; Risk Assessment; Risk Factors; Stroke

2009
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2009, Volume: 29, Issue:11

    Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Heptanoic Acids; Immunohistochemistry; Intracranial Embolism; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Stroke; Time Factors; Tissue Plasminogen Activator

2009
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Neurology, 2009, Sep-08, Volume: 73, Issue:10

    Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Secondary Prevention; Stroke

2009
The results support the use of atorvastatin in elderly patients with recent stroke or TIA.
    Neurology, 2009, Sep-08, Volume: 73, Issue:10

    Topics: Aged; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Stroke

2009
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:2

    Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System

2010
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
    Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors

2009
Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Apoptosis; Calpain; Caspase 3; Cell Proliferation; Cerebral Arteries; Disease Models, Animal; Endothelial Cells; Indoles; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Necrosis; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Sprague-Dawley; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2010
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
    Brain research, 2010, Apr-14, Volume: 1325

    Topics: Acute Disease; Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Capillary Permeability; Down-Regulation; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phospholipases A2, Cytosolic; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke; Time Factors

2010
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5

    Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States

2010
Charting new territory by simulated modeling of a clinical trial.
    Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5

    Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome

2010
Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
    Vascular health and risk management, 2010, Apr-15, Volume: 6

    Topics: Age Factors; Aged; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Stroke; Treatment Outcome

2010
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
    Clinical neuropharmacology, 2010, Volume: 33, Issue:3

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome

2010
High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
    JPMA. The Journal of the Pakistan Medical Association, 2010, Volume: 60, Issue:6

    Topics: Atorvastatin; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pakistan; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome

2010
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Revista de neurologia, 2010, Jul-01, Volume: 51, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Models, Theoretical; Myocardial Infarction; Placebos; Pyrroles; Risk Factors; Secondary Prevention; Spain; Stroke; Treatment Outcome; Young Adult

2010
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
    Brain research, 2011, Jan-12, Volume: 1368

    Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Male; Neurons; Pyrroles; Rats; Rats, Zucker; Stroke

2011
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
    Inflammopharmacology, 2011, Volume: 19, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria; Motor Activity; Movement Disorders; Neurons; Organ Specificity; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Stroke; Tetrazoles

2011
Statins before stents: does an ounce of prevention improve outcomes?
    The Canadian journal of cardiology, 2010, Volume: 26, Issue:9

    Topics: Atorvastatin; Biomarkers; Carotid Artery Diseases; Creatine Kinase, MB Form; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome; Troponin I; Troponin T

2010
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
    Brain research, 2011, Mar-25, Volume: 1382

    Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke

2011
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians.
    American heart journal, 2011, Volume: 161, Issue:4

    Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome

2011
Fabry disease and Factor V Leiden: a potent vascular risk combination.
    Internal medicine journal, 2011, Volume: 41, Issue:5

    Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin

2011
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:6

    Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid Stenosis; Clopidogrel; Colitis, Ulcerative; Female; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Lipoprotein(a); Magnetic Resonance Imaging; Middle Aged; Pyrroles; Risk Factors; Stroke; Thrombosis; Ticlopidine; Ultrasonography

2011
Drug repurposing for vascular protection after acute ischemic stroke.
    Acta neurochirurgica. Supplement, 2011, Volume: 111

    Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries

2011
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.
    European heart journal, 2012, Volume: 33, Issue:4

    Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Stroke

2012
Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature.
    Journal of neurointerventional surgery, 2012, Volume: 4, Issue:3

    Topics: Aspirin; Atorvastatin; Craniotomy; Echocardiography, Transesophageal; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Intracranial Aneurysm; Intracranial Embolism; Male; Middle Aged; Neurosurgical Procedures; Paresis; Pyrroles; Stroke; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color

2012
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
    Journal of medical economics, 2012, Volume: 15, Issue:6

    Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides

2012
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.
    Human genetics, 2012, Volume: 131, Issue:11

    Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Ischemia; Lipoprotein Lipase; Male; Middle Aged; Minisatellite Repeats; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Pyrroles; Risk Factors; Stroke

2012
Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice.
    American journal of physical medicine & rehabilitation, 2013, Volume: 92, Issue:2

    Topics: Animals; Atorvastatin; Behavior, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuropsychological Tests; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrroles; Recovery of Function; Sildenafil Citrate; Stroke; Sulfones

2013
Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: follow-up of the ATHEROMA trial.
    Cerebrovascular diseases (Basel, Switzerland), 2012, Volume: 34, Issue:2

    Topics: Aged; Atorvastatin; Carotid Artery Diseases; Contrast Media; Dextrans; Diabetes Complications; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Macrophage Activation; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke

2012
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
    Postgraduate medical journal, 2013, Volume: 89, Issue:1048

    Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Anterior Cerebral Artery; Magnetic Resonance Angiography; Male; Platelet Aggregation Inhibitors; Pyrroles; Stroke

2013
Asymptomatic carotid stenosis.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents

2013
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Current medical research and opinion, 2002, Volume: 18, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom

2002
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
    Journal of hypertension, 2003, Volume: 21, Issue:2

    Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation

2003
Withdrawal of statin treatment abrogates stroke protection in mice.
    Stroke, 2003, Volume: 34, Issue:2

    Topics: Animals; Aorta; Atorvastatin; Bleeding Time; Blood Coagulation; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Stroke; Substance Withdrawal Syndrome; Vena Cava, Inferior; Venous Thrombosis

2003
New lipid-lowering combo proves successful.
    Circulation, 2003, May-20, Volume: 107, Issue:19

    Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome

2003
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke.
    Annals of neurology, 2003, Volume: 53, Issue:6

    Topics: Animals; Antibodies; Atorvastatin; Brain; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neovascularization, Physiologic; Neuronal Plasticity; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Stroke; Synapses; Vascular Endothelial Growth Factor Receptor-2

2003
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
    The American journal of cardiology, 2003, Aug-01, Volume: 92, Issue:3

    Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome

2003
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
    Prescrire international, 2003, Volume: 12, Issue:66

    Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome

2003
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:6

    Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke

2004
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
    Archives of neurology, 2004, Volume: 61, Issue:6

    Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone

2004
Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat.
    The Journal of pharmacy and pharmacology, 2004, Volume: 56, Issue:7

    Topics: Animals; Atorvastatin; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Pyrroles; Rats; Rats, Inbred SHR; Stroke

2004
[Statins and hypertension].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2004, Sep-09, Volume: 124, Issue:17

    Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke

2004
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
    Health news (Waltham, Mass.), 2004, Volume: 10, Issue:10

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke

2004
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2005, Volume: 25, Issue:2

    Topics: Animals; Atorvastatin; Brain-Derived Neurotrophic Factor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Neovascularization, Physiologic; Neuronal Plasticity; Pyrroles; Rats; Recovery of Function; Stem Cells; Stroke; Vascular Endothelial Growth Factor A

2005
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Der Internist, 2005, Volume: 46, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome

2005
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2005, Volume: 25, Issue:6

    Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator

2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
    The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17

    Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke

2005
Statins for high-risk patients without heart disease or high cholesterol.
    The Medical letter on drugs and therapeutics, 2006, Jan-02, Volume: 48, Issue:1225

    Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke

2006
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
    Current atherosclerosis reports, 2006, Volume: 8, Issue:1

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke

2006
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine

2006
Statins and stroke: current clinical practice.
    Stroke, 2006, Volume: 37, Issue:5

    Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke

2006
The logistic transform for bounded outcome scores.
    Biostatistics (Oxford, England), 2007, Volume: 8, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Computer Simulation; Coronary Disease; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Tissue Plasminogen Activator

2007
MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
    Journal of the neurological sciences, 2006, Jul-15, Volume: 246, Issue:1-2

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Data Interpretation, Statistical; Heptanoic Acids; Intracranial Embolism; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Microcirculation; Microscopy, Fluorescence; Plasminogen Activators; Pyrroles; Rats; Rats, Wistar; Recombinant Proteins; Stroke

2006
[After TIA and stroke: a statin for secondary prevention?].
    MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24

    Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Placebos; Pyrroles; Recurrence; Stroke; Time Factors

2006
Stroke--an equal opportunity for the initiation of statin therapy.
    The New England journal of medicine, 2006, Aug-10, Volume: 355, Issue:6

    Topics: Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Stroke

2006
Statins and cerebral vasomotor reactivity: implications for a new therapy?
    Stroke, 2006, Volume: 37, Issue:10

    Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial

2006
Atorvastatin for stroke prevention.
    The Medical letter on drugs and therapeutics, 2006, Sep-11, Volume: 48, Issue:1243

    Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors

2006
Statin therapy after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22

    Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases

2006
Statin therapy after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Severity of Illness Index; Stroke

2006
Statin therapy after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22

    Topics: Atorvastatin; Conflict of Interest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Risk; Secondary Prevention; Stroke

2006
Statin therapy after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22

    Topics: Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk; Secondary Prevention; Stroke

2006
Statin therapy after stroke or transient ischemic attack.
    The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22

    Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis

2006
Statin effective in preventing recurrent stroke.
    DukeMedicine healthnews, 2006, Volume: 12, Issue:11

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Stroke

2006
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
    Nederlands tijdschrift voor geneeskunde, 2007, Mar-03, Volume: 151, Issue:9

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke

2007
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
    Revue medicale de Liege, 2007, Volume: 62, Issue:4

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States

2007
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
    Brain research, 2007, Sep-12, Volume: 1169

    Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome

2007
Discontinuation of statin therapy and clinical outcome after ischemic stroke.
    Stroke, 2007, Volume: 38, Issue:10

    Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Simvastatin; Stroke; Substance Withdrawal Syndrome

2007
Higher dose of statin medication may be better for older adults.
    Mayo Clinic women's healthsource, 2007, Volume: 11, Issue:12

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Stroke

2007
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
    Stroke, 2008, Volume: 39, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Disease Models, Animal; Heptanoic Acids; Homeodomain Proteins; Male; Middle Cerebral Artery; Neurons; Presenilin-1; Pyrroles; Rats; Rats, Wistar; Receptor, Notch1; Signal Transduction; Stem Cells; Stroke; Transcription Factor HES-1

2008
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
    Journal of the cardiometabolic syndrome, 2008,Winter, Volume: 3, Issue:1

    Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke

2008
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
    Journal des maladies vasculaires, 2008, Volume: 33, Issue:2

    Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvastatin; Calcinosis; Heptanoic Acids; Humans; Intracranial Embolism; Male; Pyrroles; Stroke; Tomography, X-Ray Computed

2008
Natural statins and stroke.
    Circulation, 2000, Jan-25, Volume: 101, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fibrinogen; Heptanoic Acids; Humans; Pyrroles; Risk Factors; Stroke

2000
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
    The American journal of cardiology, 2000, Nov-15, Volume: 86, Issue:10

    Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome

2000